U.S. Markets open in 3 hrs 8 mins
  • S&P Futures

    3,817.25
    -28.75 (-0.75%)
     
  • Dow Futures

    30,817.00
    -265.00 (-0.85%)
     
  • Nasdaq Futures

    13,317.50
    -78.00 (-0.58%)
     
  • Russell 2000 Futures

    2,115.70
    -22.80 (-1.07%)
     
  • Crude Oil

    51.70
    -1.43 (-2.69%)
     
  • Gold

    1,851.00
    -14.90 (-0.80%)
     
  • Silver

    25.32
    -0.53 (-2.07%)
     
  • EUR/USD

    1.2183
    +0.0010 (+0.0853%)
     
  • 10-Yr Bond

    1.1090
    0.0000 (0.00%)
     
  • Vix

    23.10
    +1.52 (+7.04%)
     
  • GBP/USD

    1.3670
    -0.0061 (-0.4415%)
     
  • USD/JPY

    103.6900
    +0.1850 (+0.1787%)
     
  • BTC-USD

    31,914.70
    +1,430.96 (+4.69%)
     
  • CMC Crypto 200

    632.84
    +22.84 (+3.75%)
     
  • FTSE 100

    6,667.37
    -48.05 (-0.72%)
     
  • Nikkei 225

    28,631.45
    -125.41 (-0.44%)
     

Pfizer-BioNTech seeks full marketing approval from UK for COVID-19 vaccine

·1 min read

LONDON, Dec 2 (Reuters) - Pfizer is seeking full marketing authorisation from Britain for its COVID-19 vaccine, an executive said on Wednesday as the U.S. drugmaker gears up to deliver by the weekend the first shots following approval for emergency use in the country.

The application for full approval is "in parallel" with emergency use, said Berkeley Phillips, medical director of Pfizer UK, in a briefing.

He said regulators will review the same data provided for the emergency use by Pfizer and its partner and BioNTech for the full approval. He did not say when that decision may come.

Deliveries to Britain could not have started until the regulators had given their go ahead, he said. Regulators will assess each batch of the vaccine for quality. (Reporting by Alistair Smout and Kate Kelland in London, John Miller in Zurich and Ludwig Burger in Frankfurt; Writing by Josephine Mason; Editing by Louise Heavens)